Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal-Reference-Cited by-同舟云学术

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal

Published:2015-04 Issue:1 Volume:88 Page:16-23
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Togashi Yosuke,Hayashi Hidetoshi,Okamoto Kunio,Fumita Soichi,Terashima Masato,de Velasco Marco A.,Sakai Kazuko,Fujita Yoshihiko,Tomida Shuta,Nakagawa Kazuhiko,Nishio Kazuto

Funder

Third-Term Comprehensive 10-Year Strategy for Cancer Control

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Cancer treatment and survivorship statistics, 2012;Siegel;CA Cancer J Clin,2012

3. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

4. New driver mutations in non-small-cell lung cancer;Pao;Lancet Oncol,2011

5. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nicotine up-regulates SLC7A5 expression depending on TRIM29 in non-small cell lung cancer;Genes & Diseases;2024-03

2. Toxicological Aspects Associated with Consumption from Electronic Nicotine Delivery System (ENDS): Focus on Heavy Metals Exposure and Cancer Risk;International Journal of Molecular Sciences;2024-02-27

3. The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review;Critical Reviews in Oncology/Hematology;2024-02

4. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis;Clinical Medicine Insights: Oncology;2023-01

5. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study;The Oncologist;2022-10-01